Regulatory News In Brief
This article was originally published in The Gray Sheet
Executive SummaryDirect-to-consumer genetics tests panel
You may also be interested in...
An FDA determination of substantial risk of illness and injury from use of absorbable powdered surgical gloves has sparked a proposed product ban by the agency.
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.